Howard M. Fillit
#145,510
Most Influential Person Now
Howard M. Fillit's AcademicInfluence.com Rankings
Howard M. Fillitphilosophy Degrees
Philosophy
#7811
World Rank
#11069
Historical Rank
Logic
#4848
World Rank
#6177
Historical Rank

Download Badge
Philosophy
Howard M. Fillit's Degrees
- Masters Neurobiology and Behavior Columbia University
Why Is Howard M. Fillit Influential?
(Suggest an Edit or Addition)Howard M. Fillit's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. (1990) (2616)
- Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. (2004) (1207)
- A call for transparent reporting to optimize the predictive value of preclinical research (2012) (1036)
- Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) (716)
- Elevated circulating tumor necrosis factor levels in Alzheimer's disease (1991) (494)
- Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 (2022) (445)
- Observations in a preliminary open trial of estradiol therapy for senile dementia-alzheimer's type (1986) (374)
- Achieving and maintaining cognitive vitality with aging. (2002) (306)
- Improving dementia care: The role of screening and detection of cognitive impairment (2013) (227)
- Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders (1994) (223)
- Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study (2018) (204)
- Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology (2016) (201)
- Cardiovascular risk factors and dementia. (2008) (200)
- Biomarkers of aging: from primitive organisms to humans. (2004) (188)
- Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare (2002) (185)
- Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE (2015) (161)
- Cost of Alzheimer's Disease and Related Dementia in Managed‐Medicare (1999) (153)
- Developing novel blood-based biomarkers for Alzheimer's disease (2014) (146)
- The Vascular Impairment of Cognition Classification Consensus Study (2017) (140)
- Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (136)
- The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis (1994) (134)
- The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease (2020) (133)
- The Frailty Identity Crisis (2009) (125)
- Recommendations for best practices in the treatment of Alzheimer's disease in managed care. (2006) (111)
- Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies (2011) (111)
- Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes [see comments] (1994) (110)
- Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer’s disease and related disorders (2012) (109)
- Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease (2007) (101)
- Heparin Oligosaccharides that Pass the Blood‐Brain Barrier Inhibit β‐Amyloid Precursor Protein Secretion and Heparin Binding to β‐Amyloid Peptide (1998) (98)
- Cardiovascular disease risk factors and cognitive impairment. (2006) (94)
- Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. (2002) (93)
- Should older adults be screened for dementia? It is important to screen for evidence of dementia! (2007) (92)
- Alzheimer's Disease–Related Dementias Summit 2016: National research priorities (2017) (91)
- Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide (1993) (88)
- The role of hormone replacement therapy in the prevention of Alzheimer disease. (2002) (87)
- Optimizing Coding and Reimbursement to Improve Management of Alzheimer's Disease and Related Dementias (2002) (86)
- Estrogens in the Pathogenesis and Treatment of Alzheimer's Disease in Postmenopausal Women (1994) (84)
- Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews. (1999) (83)
- The pharmacoeconomics of Alzheimer's disease. (2000) (79)
- Antibodies to basement membrane collagen and to laminin are present in sera from patients with poststreptococcal glomerulonephritis (1986) (76)
- Apolipoprotein E‐derived peptides reduce CNS inflammation: implications for therapy of neurological disease (2006) (75)
- IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders (2009) (75)
- Non-coding variability at the APOE locus contributes to the Alzheimer’s risk (2019) (74)
- Translating the biology of aging into novel therapeutics for Alzheimer disease (2018) (72)
- Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis (2016) (71)
- Binding of heparan sulfate glycosaminoglycan to β‐amyloid peptide: inhibition by potentially therapeutic polysulfated compounds (1994) (71)
- Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide (1993) (69)
- Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions (2015) (69)
- Antivascular antibodies in the sera of patients with senile dementia of the Alzheimer's type. (1987) (69)
- Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer’s Disease and Other Dementias (2012) (68)
- From bedside to bench: does mental and physical activity promote cognitive vitality in late life? (2006) (68)
- The Effect of Dementia on Acute Care in a Geriatric Medical Unit (1992) (67)
- 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease (2014) (65)
- Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. (1994) (65)
- Current evidence for the clinical use of long-chain polyunsaturated N-3 fatty acids to prevent age-related cognitive decline and Alzheimer’s disease (2013) (64)
- Immunohistochemical identification of thrombospondin in normal human brain and in Alzheimer's disease. (1992) (64)
- Sera from patients with poststreptococcal glomerulonephritis contain antibodies to glomerular heparan sulfate proteoglycan (1985) (64)
- Dependence as a unifying construct in defining Alzheimer's disease severity (2010) (62)
- Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development (2013) (62)
- A Prospective Study of the Effect of Hypertension and Baseline Blood Pressure on Cognitive Decline and Dementia in Postmenopausal Women: The Women's Health Initiative Memory Study (2008) (61)
- Economics of dementia and pharmacoeconomics of dementia therapy. (2005) (60)
- Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (56)
- Patterns of healthcare utilization and costs for vascular dementia in a community-dwelling population. (2005) (54)
- Practicality of a computerized system for cognitive assessment in the elderly (2008) (53)
- Serial studies on circulating immune complexes in post-streptococcal sequelae. (1978) (52)
- The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (52)
- Impact of Donepezil on Caregiving Burden for Patients With Alzheimer's Disease (2000) (52)
- Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data (2017) (51)
- The costs of vascular dementia A comparison with Alzheimer's disease (2002) (51)
- Renal Disease in the Geriatric Patient (1984) (50)
- Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer’s disease (2014) (50)
- House calls: a practical guide to seeing the patient at home. (1995) (50)
- A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium (2008) (50)
- Cellular reactivity to altered glomerular basement membrane in glomerulonephritis. (1978) (49)
- The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier) (2013) (49)
- Thiobarbituric acid reactive material in uremic blood. (1981) (48)
- Decisions for and against resuscitation in an acute geriatric medicine unit serving the frail elderly. (1992) (46)
- Methodological issues in primary prevention trials for neurodegenerative dementia. (2009) (44)
- Aducanumab and the FDA — where are we now? (2021) (44)
- Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. (1994) (43)
- The role of anthropometry in the assessment of malnutrition in the hospitalized frail elderly. (1993) (43)
- Overcoming obstacles to repurposing for neurodegenerative disease (2014) (42)
- Cellular immunity in glomerulonephritis. (1982) (41)
- Findings from the National Memory Screening Day Program (2015) (40)
- Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease (2017) (39)
- Alzheimer's disease research and development: a call for a new research roadmap (2014) (39)
- The Nonuse of Urethral Catheterization in the Management of Urinary Incontinence in the Teaching Nursing Home (1983) (38)
- The effect of donepezil therapy on health costs in a Medicare managed care plan. (2002) (38)
- Usefulness of the Neurobehavioral Cognitive Status Examination in the Hospitalized Elderly (1992) (38)
- Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. (1998) (38)
- Monoclonal antibodies to heparan sulfate proteoglycan: development and application to the study of normal tissue and pathologic human kidney biopsies. (1988) (38)
- Autoantibodies to the protein core of vascular basement membrane heparan sulfate proteoglycan in systemic lupus erythematosus. (1993) (38)
- Beyond amyloid: the future of therapeutics for Alzheimer's disease. (2012) (36)
- Heparin promotes ß-secretase cleavage of the Alzheimer's amyloid precursor protein (1997) (36)
- Evaluation of the Neuroprotective Potential of N-Acetylcysteine for Prevention and Treatment of Cognitive Aging and Dementia. (2017) (36)
- Induction of antibodies to hyaluronic acid by immunization of rabbits with encapsulated streptococci (1986) (35)
- New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures (2019) (35)
- Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (35)
- Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis (2021) (34)
- The Quest for Immortality: Science at the Frontiers of Aging (2001) (34)
- Large-scale genomics unveil polygenic architecture of human cortical surface area (2015) (34)
- Donepezil use in managed Medicare: effect on health care costs and utilization. (1999) (34)
- Masculine vitality: pros and cons of testosterone in treating the andropause. (2004) (33)
- Dementia diagnosis disparities by race and ethnicity (2020) (32)
- Validation of a brief screen for cognitive impairment (BSCI) administered by telephone for use in the medicare population. (2005) (32)
- Antibodies to vascular heparan sulfate proteoglycan in patients with systemic lupus erythematosus. (1991) (32)
- Older Americans' Risk-benefit Preferences for Modifying the Course of Alzheimer Disease (2009) (31)
- Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation (2017) (31)
- Regulation of the Heparan Sulfate Proteoglycan, Perlecan, by Injury and Interleukin‐1α (1999) (31)
- Specificities of heparin-binding sites from the amino-terminus and type 1 repeats of thrombospondin-1. (2000) (31)
- Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease. (2017) (31)
- Alzheimer's Disease Drug Development (2022) (30)
- Disorders of the extracellular matrix and the pathogenesis of senile dementia of the Alzheimer's type. (1995) (30)
- Optimization of an alcian blue dot-blot assay for the detection of glycosaminoglycans and proteoglycans. (1991) (30)
- New directions for frontotemporal dementia drug discovery (2008) (30)
- Identification of Alcoholism and Depression in a Geriatric Medicine Outpatient Clinic (1993) (30)
- Monoclonal antibodies to heparan sulfate inhibit the formation of thrombin-antithrombin III complexes. (1993) (30)
- Brocklehurst's Textbook of Geriatric Medicine and Gerontology Fillit Howard M Rockwood Kenneth and Young John Brocklehurst's Textbook of Geriatric Medicine and Gerontology 1168pp £164.69 Elsevier 9780702061851 0702061859 [Formula: see text]. (2003) (30)
- The Economic Benefits of Acetylcholinesterase Inhibitors for Patients with Alzheimer Disease and Associated Dementias (2004) (30)
- Barriers to drug discovery and development for Alzheimer disease. (2002) (28)
- Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) (28)
- Immunogenicity of liposome-bound hyaluronate in mice. At least two different antigenic sites on hyaluronate are identified by mouse monoclonal antibodies (1988) (27)
- Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease. (2014) (27)
- Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer's disease (1987) (26)
- Identification of antigenic epitopes in type IV collagen by use of synthetic peptides. (1993) (25)
- Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. (2005) (24)
- Costs of Early Stage Alzheimer’s Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1 (2020) (23)
- Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis (2019) (22)
- Cognitive decline : strategies for prevention (1997) (21)
- AIDS in the elderly: a case and its implications. (1989) (21)
- 18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery (2018) (21)
- Heparin promotes beta-secretase cleavage of the Alzheimer's amyloid precursor protein. (1997) (21)
- Probable Heterosexual Transmission of AIDS in an Aged Woman (1992) (20)
- Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease. (2021) (20)
- Studies of hospital social stays in the frail elderly and their relationship to the intensity of social work intervention. (1993) (20)
- Accelerating Alzheimer's disease drug innovations from the research pipeline to patients (2018) (20)
- A Brain Capital Grand Strategy: toward economic reimagination (2020) (20)
- A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients (2017) (20)
- The neurobiology of gonadal hormones and cognitive decline in late life. (1997) (19)
- Real-Time Digital Contact Tracing: Development of a System to Control COVID-19 Outbreaks in Nursing Homes and Long-Term Care Facilities (2020) (19)
- A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data (2019) (19)
- Translating Current Knowledge Into Dementia Prevention (2012) (19)
- Obtaining Informed Consent in the Teaching Nursing Home (1983) (19)
- Racial and Ethnic Differences in Knowledge About One's Dementia Status. (2020) (18)
- Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer’s disease (2007) (17)
- Autoimmunity to cholinergic‐specific antigens of the brain in senile dementia of the Alzheimer's type (1988) (16)
- Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease (2021) (15)
- Health economics and the value of therapy in Alzheimer’s disease (2007) (14)
- Vascular dementia: stroke prevention takes on new urgency. (1993) (14)
- Drug discovery for Alzheimer’s disease (2007) (14)
- Cytotoxicity to endothelial cells by sera from aged MRL/lpr/lpr mice is associated with autoimmunity to cell surface heparan sulfate. (1995) (14)
- Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia (2021) (13)
- A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline (2016) (13)
- Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force (2019) (13)
- Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease. (2010) (13)
- Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making. (2014) (12)
- A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease (2016) (12)
- Novel strategies for the prevention of dementia from Alzheimer's disease (2009) (12)
- Artificial Intelligence–Powered Digital Health Platform and Wearable Devices Improve Outcomes for Older Adults in Assisted Living Communities: Pilot Intervention Study (2020) (12)
- How the principles of geriatric assessment are shaping managed care. (1998) (12)
- Use of ineffective or unsafe medications among members of a Medicare HMO compared to individuals in a Medicare fee-for-service program. (1997) (11)
- Association of autoimmunity to vascular heparan sulfate proteoglycan and vascular disease in the aged. (1993) (11)
- Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders (2012) (11)
- Challenges for Acute Care Geriatric Inpatient Units Under the Present Medicare Prospective Payment System (1994) (11)
- Clinical immunology of aging (1994) (11)
- NATIONAL ESTIMATES OF POTENTIALLY AVOIDABLE HOSPITALIZATIONS AMONG MEDICARE BENEFICIARIES WITH ALZHEIMER’S DISEASE AND RELATED DEMENTIAS (2016) (10)
- Future Therapeutic Developments of Estrogen Use (1995) (10)
- Therapeutics for cognitive aging (2010) (10)
- Observation of Patient and Caregiver Burden Associated with Early Alzheimer’s Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1 (2019) (10)
- Autoimmune markers in HIV-associated dementia (2003) (10)
- Antibodies in Serum of Patients with Alzheimer's Disease Cause Immunolysis of Cholinergic Nerve Terminals from the Rat Cerebral Cortex (1989) (9)
- Low flow continuous peritoneal dialysis in acute renal failure. (1981) (9)
- Strategies for drug discovery for cognitive aging and alzheimer’s disease (2002) (9)
- FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2020) (9)
- Value-Generating Exploratory Trials in Neurodegenerative Dementias (2021) (8)
- A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensamble and on multivariate algorithms, to characterize late onset Alzheimer’s disease (2020) (8)
- Proteoglycans and the acute-phase response in Alzheimer's disease brain (1994) (8)
- Evidence needs to be translated, whether or not it is complete. (2014) (8)
- Intravenous immunoglobulins for Alzheimer's disease (2004) (8)
- Advancing drug discovery for Alzheimer's disease. (2005) (7)
- Neurogenesis as a therapeutic strategy for cognitive aging and Alzheimer's disease. (2006) (7)
- Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia (2020) (7)
- Drug discovery and the prevention of Alzheimer’s disease (2008) (7)
- Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias (2011) (7)
- Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization (2021) (7)
- The effect of a fitness program on health status and health care consumption in Medicare MCOs. (2001) (7)
- Meeting the unique challenges of drug discovery for neurodegenerative diseases (2009) (7)
- Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference (2018) (6)
- Cost consequences and cost benefits of treating patients with moderate to severe Alzheimer disease (2005) (6)
- Comprar Brocklehurst's Textbook Of Geriatric Medicine And Gerontology 8th Ed. | Howard Fillit | 9780702061851 | Elsevier España (2016) (6)
- Racial and Ethnic Differences in Hospice Use and Hospitalizations at End-of-Life Among Medicare Beneficiaries With Dementia (2022) (6)
- Studies of the cellular immune response to heparan sulfate proteoglycan in the tight skin mouse. (1993) (6)
- Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force (2021) (6)
- Autoimmune MRL mice express high-affinity IgG2b monoclonal autoantibodies to heparin. (1996) (6)
- Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery (2013) (6)
- Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (6)
- An analysis of global research funding for the frontotemporal dementias: 1998–2008 (2011) (6)
- Partnerships between philanthropy, government and industry are needed to advance drug discovery for neurodegenerative diseases. (2006) (6)
- Interleukin-1 and nerve growth factor induce hypersecretion and hypersulfation of neuroblastoma proteoglycans which bind β-amyloid (1995) (6)
- New directions in neuroprotection: basic mechanisms, molecular targets and treatment strategies. (2005) (6)
- Vascular dementia: how to make the diagnosis in office practice. (1993) (6)
- In vitro correlates of endothelial injury and repair. (1982) (6)
- Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil (2010) (5)
- A Brief Telephonic Instrument to Screen for Cognitive Impairment in a Managed Care Population (2003) (5)
- Economics, pharmacoeconomics and drug discovery for dementias. (2002) (5)
- IPECAD5 — Fifth International Pharmaco-Economic Conference on Alzheimer’s Disease (2009) (5)
- IPECAD5--Fifth International Pharmaco-Economic Conference on Alzheimer's Disease. (2010) (5)
- Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer’s disease clinical trials (2014) (5)
- An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease (2022) (5)
- Improving Early Recognition of Alzheimer's Disease: A Review of Telephonic Screening Tools (2001) (5)
- Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review (2020) (5)
- Analysis of Episodes of Care in Medicare Beneficiaries Newly Diagnosed with Alzheimer's Disease (2018) (5)
- The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (5)
- Tau and Alzheimer’s disease (2002) (4)
- Tau and Alzheimer's disease: the long road to anti-tangle therapeutics. (2002) (4)
- Clinical trials: new opportunities. (2012) (4)
- Commentary on “The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006.” Clinical guidelines are not enough: System-wide, population-based programs are needed to improve the care of patients with Alzheimer’s disease and related dementias (2007) (4)
- Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery (2014) (4)
- Vascular dementia: an updated approach to patient management. A roundtable discussion: Part 3. (1994) (4)
- Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease (2013) (4)
- Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (3)
- Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials (2022) (3)
- Tumor necrosis factor-alpha alters the metabolism of endothelial cell proteoglycans. (1994) (3)
- Investing in Late-Life Brain Capital (2022) (3)
- Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment (2022) (3)
- Making geriatric assessment an asset to your primary care practice. (1994) (3)
- Comprar Brocklehurst's Textbook of Geriatric Medicine and Gerontology, 7th Edition | Howard Fillit | 9781416062318 | Churchill Livingstone (2010) (3)
- Optimizing the use of CROs by academia and small companies (2013) (3)
- CHAPTER 1 – Introduction: Aging, Frailty, and Geriatric Medicine (2010) (3)
- The Road Ahead To Cure And Prevent Alzheimer's Disease: Implementing Prevention into Primary Care. (2015) (3)
- Practical Geriatric Assessment (1998) (2)
- A diverse portfolio of novel drug discovery efforts for Alzheimer's disease: Meeting report from the 11th International Conference on Alzheimer's Drug Discovery, 27-28 September 2010, Jersey City, NJ, USA (2010) (2)
- Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID‐19 pandemic (2021) (2)
- PHARMACOLOGIC TREATMENT OF ALZHEIMER'S DISEASE: EFFICACY, DOSING, AND CONTROVERSIES (2007) (2)
- The Effects of Rasagiline on Glucose Metabolism and Cognition and Their Relationship to Tau Burden in a Double-Blind, Placebo-Controlled Phase Ii Clinical Trial of Participants with Alzheimer's Dementia (2020) (2)
- The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease (2020) (2)
- P3-483: Memantine discontinuation in nursing home residents with Alzheimer's disease was associated with an increase in Alzheimer's disease symptoms (2008) (2)
- Monoclonal antibody to heparan sulfate from autoimmune tight skin (TSK) mice binds to the endothelial cell surface. (1997) (2)
- A multi-targeted approach for a complex multifaceted disease. (2009) (2)
- The geriatric evaluation and treatment unit: a model site for acute care of the frail elderly, education, and research. (1993) (2)
- Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery (2014) (1)
- Interleukin-1 and nerve growth factor induce hypersecretion and hypersulfation of neuroblastoma proteoglycans which bind beta-amyloid. (1995) (1)
- Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil. (2010) (1)
- O4-04-01 A hierarchical approach to practical assessment of cognitive decline in the elderly (2006) (1)
- Prevention of cognitive dysfunction following surgery: An unmet clinical opportunity (2016) (1)
- Letter to the Editor re: Nexus of Cancer & Alzheimer's (2017) (1)
- Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and stroke (2009) (1)
- Real-Time Digital Contact Tracing: Development of a System to Control COVID-19 Outbreaks in Nursing Homes and Long-Term Care Facilities (Preprint) (2020) (1)
- Acute care of dementia patients: specialized programs needed. (1994) (1)
- Heritability of regional brain volumes in large-scale neuroimaging and genetic studies (2017) (1)
- Geriatrics and Health Care Reform: Opportunities in Managed Care for Preserving Excellence in the Care of the Elderly (1994) (1)
- Frontotemporal Degeneration , the Next Therapeutic Frontier : Molecules and Animal Models for FTD drug development ( Part 1 of 2 articles ) (2013) (1)
- Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment (2022) (1)
- Discontinuation of Memantine Therapy in Nursing Home Residents With Alzheimer’s Disease is Associated With Increased Utilization of Psychotropic Medications and Decreased Body Weight (2008) (1)
- 30-DAY HOSPITAL READMISSIONS AMONG MEDICARE BENEFICIARIES WITH ALZHEIMER’S DISEASE AND RELATED DEMENTIAS PRIOR TO AND FOLLOWING DIAGNOSIS (2016) (1)
- Getting More Clinically Meaningful Measures of Functional Impairment for Alzheimer's Disease. (2017) (1)
- The Advantages of FTD Drug Development ( Part 2 of FTD : The Next Therapeutic Frontier ) (2013) (1)
- SINGLE ENDPOINT FOR NEW DRUG APPROVALS FOR ALZHEIMER ’ S DISEASE (2017) (1)
- Reversible acquired immunodeficiency in the elderly: A review (1991) (1)
- Sara and George and Justice (2004) (1)
- Our Parents, Ourselves: How American Health Care Imperils Middle Age and Beyond (2006) (1)
- Distribution of the Iron-Binding Protein Lactoferrin in the Pathological Lesions of Neurodegenerative Diseases (1997) (1)
- Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer’s Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers? (2018) (0)
- Artificial Intelligence–Powered Digital Health Platform and Wearable Devices Improve Outcomes for Older Adults in Assisted Living Communities: Pilot Intervention Study (Preprint) (2020) (0)
- The need for a harmonized speech dataset for Alzheimer’s disease biomarker development (2020) (0)
- Alzheimer’s disease medication utilization patterns: Disparities in treatment initiation, non‐adherence, and discontinuation (2021) (0)
- Improved screening approach for MCI and dementia in the elderly (2005) (0)
- PND6 COST-EFFECTIVENESS OF SCREENING FOR COGNITIVE IMPAIRMENT IN OLDER POPULATIONS: IMPLICATIONS FOR ALZHEIMER'S DISEASE CARE (2007) (0)
- Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty (2017) (0)
- Alzheimer Disease: New Drugs in the Offing? (2017) (0)
- 2016 Antiaging Medicine (2016) (0)
- P2-430: The association between use of intravenous immunoglobulin and risk of Alzheimer's disease and related disorders (2008) (0)
- Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
- Brief Screen for Cognitive Impairment (2018) (0)
- The Relevance of Assessing Cognitive Performances in Patients With Cerebrovascular (2016) (0)
- Our parents, ourselves . Author's reply (2006) (0)
- Alzheimer's disease drug discovery: Abeta and beyond. (2010) (0)
- BASELINE FINDINGS FROM GERAS-US: A LONGITUDINAL COHORT STUDY OF RESOURCE USE AND COSTS OF MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE (AD) IN THE UNITED STATES (2018) (0)
- Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
- The Neurofilament Surveillance Project (NSP): A biomarker study to sample blood quarterly in familial frontotemporal lobar degeneration (2022) (0)
- New concepts of glomerular injury. (1984) (0)
- Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease (2013) (0)
- P3-408 Healthcare costs of vascular dementia in community-dwelling patients (2004) (0)
- Current and future option sin the treatment of Alzheimer's disease (2003) (0)
- Impact of agitation in long‐term care residents with dementia in the United States (2021) (0)
- Racial and Ethnic Differences in Hospice Use and End‐of‐life Hospitalizations among Medicare Beneficiaries with Dementia (2022) (0)
- An Update on Healthcare Resource Use and Economic Burden In Alzheimer's Disease In The United States (Us) From A Medicare Sample Analysis. (2015) (0)
- Practical evaluation of secondary immune deficiencies in the elderly. (1991) (0)
- New strategy for alzheimer'S. (2019) (0)
- 20 Novel programs in drug discovery for Alzheimer's disease (2012) (0)
- Chemical Composition of Antigenic Preparations (0)
- A NOVEL APPROACH TO STUDY HEALTHCARE RESOURCE USE AND COSTS OF CARE AMONG MEDICARE-ENROLLED PATIENTS DURING AND AFTER PARTICIPATING IN CLINICAL TRIALS FOR EARLY ALZHEIMER'S DISEASE (2019) (0)
- Disease progression and costs at the 3‐year follow‐up of the GERAS‐US study (2023) (0)
- Perspective Developing novel blood-based biomarkers for Alzheimer's disease (2014) (0)
- Serial studies oncirculating immunecomplexes inpost-streptococc al sequelae (1978) (0)
- The effects of rasagiline on cerebral glucose metabolism, cognition, and tau in a double-blind, placebo-controlled Phase II clinical trial in Alzheimer’s dementia (2020) (0)
- Health Care Utilization and Costs in Treated and Non-Treated Patients Newly Diagnosed with Alzheimer’s Disease in the United States (2016) (0)
- Editorial [ Drug Discovery for Alzheimers Disease: Filling the Pipeline Guest Editors: Antony R. Horton and Howard M. Fillit ] (2007) (0)
- The relationship of group A streptococci and mammalian tissue antigens to certain disease states. (1979) (0)
- DISEASE PROGRESSION AND COSTS AT 1-YEAR FOLLOW-UP OF GERAS-US: A 3-YEAR STUDY OF MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE IN THE UNITED STATES (2019) (0)
- PND99 A STUDY OF PREFERENCES FOR DISEASE-MODIFYING TREATMENTS FOR ALZHEIMER’S DISEASE (2020) (0)
- End‐of‐life burdensome interventions among Medicare fee‐for‐service beneficiaries with no dementia, non‐advanced dementia, and advanced dementia (2022) (0)
- A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline (2016) (0)
- The Dawn of a New Era of Alzheimer’s Research and Drug Development (2022) (0)
- Alzheimer’s Disease Linkage to Evidence (AD-LINE) Study Early Results: Linking Real-World Claims Data to Phase III GRADUATE Study of Gantenerumab (P7-6.009) (2023) (0)
- Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery (2013) (0)
- Early Life Matters in Very Late Life (2017) (0)
- 1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France (2008) (0)
- Recognizing the Spectrum of Cognitive Impairment to Advance Drug Discovery. (2016) (0)
- Chronic nephritis after acute poststreptococcal glomerulonephritis. (1978) (0)
- The trend of disruption in the functional brain network topology of Alzheimer’s disease (2021) (0)
- Disease progression and costs at 3‐year follow‐up of GERAS‐US: A 3‐year study of mild cognitive impairment and mild dementia due to Alzheimer’s disease in the United States (2021) (0)
- NOVEL ENVELOPING MECHANISM OF ACTION OF ALZ-801: CONFORMATIONAL STABILIZATION OF BETA AMYLOID BY A SMALL MOLECULE RESULTS IN ANTI-OLIGOMER ACTIVITY (2017) (0)
- The economics and pharmacoeconomics of mild cognitive impairment (2005) (0)
- Alzheimer's disease medication use and adherence patterns by race and ethnicity (2022) (0)
- Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (0)
- Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2022) (0)
- EPISODES OF CARE AMONG MEDICARE ELIGIBLE ALZHEIMER’S DISEASE PATIENTS DIAGNOSED IN INPATIENT SETTINGS IN THE UNITED STATES (2017) (0)
- COMPARISON OF HEALTHCARE COSTS FOR ALZHEIMER’S DISEASE (AD) PATIENTS DIAGNOSED IN INPATIENT VERSUS NON-INPATIENT SETTINGS (2017) (0)
- Systemtic and reg.ional hemodynamic effects of perindopril in exp.erimentaI heart fa.ilure (1993) (0)
- P-002 The effect of individual characteristics on benefit-risk trade-offs for modifying the progression of Alzheimer’s disease (2007) (0)
- Epigenetics and Alzheimer Risk (2017) (0)
- Research activities in the Department of Geriatrics and Adult Development. (1993) (0)
- Disease progression and costs at two‐year follow‐up of GERAS‐US: A three‐year study of mild cognitive impairment and mild dementia due to Alzheimer’s disease in the United States (2020) (0)
- Satellite Symposium: Emerging Clinical Practices in AA Amyloidosis (2004) (0)
- Toward comprehensive value assessment for Alzheimer's disease innovations (2022) (0)
- Drug discovery for Alzheimer's disease: filling the pipeline. (2007) (0)
- including nonprivatized Medicare, yet never addresses argu- ments underlying my position. (2017) (0)
- Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction (2023) (0)
- Alzheimer Research Forum live discussion: lost in translation? Charting the course in preclinical therapeutic development. (2006) (0)
- TRENDS IN RACIAL AND ETHNIC DIFFERENCES IN DEMENTIA PREVALENCE RATES AND DISEASE AWARENESS (2019) (0)
- “Our Parents, Ourselves”—Reply (2006) (0)
- Contents, Vol. 39, 1993 (1993) (0)
- Senior Health Advisor, Version 1.0 (1996) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Howard M. Fillit?
Howard M. Fillit is affiliated with the following schools: